L-Threo-Dihydroxyphenylserine corrects neurochemical abnormalities in a menkes disease mouse model

Annals of Neurology

Volumn 73, Issue 2, 2013, Pages 259-265

  Donsante, Anthony ^a   Sullivan, Patricia ^b   Goldstein, David S ^b   Brinster, Lauren R ^c   Kaler, Stephen G ^a  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^b NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 DIHYDROXYPHENYLETHYLENE GLYCOL; CATECHOLAMINE; DIHYDROXYPHENYLACETIC ACID; LEVO THREO DIHYDROXYPHENYLSERINE; MENKES PROTEIN; NORADRENALIN; THREO 3,4 DIHYDROXYPHENYLSERINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ELECTROCHEMICAL DETECTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTOPATHOLOGY; MENKES SYNDROME; MOUSE; NONHUMAN; PRIORITY JOURNAL; WILD TYPE;

3,4-DIHYDROXYPHENYLACETIC ACID; ADENOSINE TRIPHOSPHATASES; ANIMALS; ANTIPARKINSON AGENTS; BLOOD-BRAIN BARRIER; BRAIN; BRAIN CHEMISTRY; CATION TRANSPORT PROTEINS; COPPER; DISEASE MODELS, ANIMAL; DOPAMINE; DOPAMINE BETA-HYDROXYLASE; DROXIDOPA; FEMALE; MALE; MENKES KINKY HAIR SYNDROME; MICE; MICE, INBRED C57BL; MICE, NEUROLOGIC MUTANTS; NERVE DEGENERATION; NOREPINEPHRINE;

EID: 84875459198     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.23787     Document Type: Article

References (27)

1. Menkes JH, Alter M, Steigleder GK, et al. A sex-linked recessive disorder with retardation of growth, peculiar hair, and focal cerebral and cerebellar degeneration. Pediatrics 1962; 29: 764-779.
2. Kaler SG,. The neurology of ATP7A copper transporter disease: emerging concepts and future trends. Nat Rev Neurol 2011; 7: 15-29.
3. Kaler SG, Goldstein DS, Holmes C, et al. Plasma and cerebrospinal fluid neurochemical pattern in Menkes disease. Ann Neurol 1993; 33: 171-175.
4. Goldstein DS, Holmes CS, Kaler SG,. Relative efficiencies of plasma catechol levels and ratios for neonatal diagnosis of Menkes disease. Neurochem Res 2009; 34: 1464-1468.
5. White SR, Reese K, Sato S, Kaler SG,. Spectrum of EEG findings in Menkes disease. Electroencephalogr Clin Neurophysiol 1991; 87: 57-61.
6. Kaler SG, Liew CJ, Donsante A, et al. Molecular correlates of epilepsy in early diagnosed and treated Menkes disease. J Inherit Metab Dis 2010; 33: 583-589.
7. Kaler SG, Holmes CS, Goldstein DS, et al. Neonatal diagnosis and treatment of Menkes disease. N Engl J Med 2008; 358: 605-614.
8. Kaler SG, Gallo LK, Proud VK, et al. Occipital horn syndrome and a mild Menkes phenotype associated with splice site mutations at the MNK locus. Nat Genet 1994; 8: 195-202.
9. Tang J, Donsante A, Desai V, et al. Clinical outcomes in Menkes disease patients with a copper-responsive ATP7A mutation, G727R. Mol Genet Metab 2008; 95: 174-181.
10. Christodoulou J, Danks DM, Sarkar B, et al. Early treatment of Menkes disease with parenteral copper-histidine: long-term follow-up of four treated patients. Am J Med Genet 1998; 76: 154-164.
11. Senard JM, Rouet P,. Dopamine-beta-hydroxylase deficiency. Orphanet J Rare Dis 2006; 1: 7.
12. Robertson D, Haile V, Perry SE, et al. Dopamine beta-hydroxylase deficiency. A genetic disorder of cardiovascular regulation. Hypertension 1991; 18: 1-8.
13. Kim C, Leung A, Huh Y, et al. Norepinephrine deficiency is caused by combined abnormal mRNA processing and defective protein trafficking of dopamine b-hydroxylase. J Biol Chem 2011; 286: 9196-9204.
14. Biaggioni I, Robertson D,. Endogenous restoration of noradrenaline by precursor therapy in dopamine-beta-hydroxylase deficiency. Lancet 1987; 2: 1170-1172.
15. Manin'tVeld AJ, Boomsma F, van den Meiracker AH, Schalekamp MA,. Effect of unnatural noradrenaline precursor on sympathetic control and orthostatic hypotension in dopamine-beta-hydroxylase deficiency. Lancet 1987; 2: 1172-1175.
16. Thomas SA, Matsumoto AM, Palmiter RD,. Noradrenaline is essential for mouse fetal development. Nature 1995; 374: 643-646.
17. Thomas SA, Marck BT, Palmiter RD, Matsumoto AM,. Restoration of norepinephrine and reversal of phenotypes in mice lacking dopamine beta-hydroxylase. J Neurochem 1998; 70: 2468-2476.
18. Donsante A, Yi L, Zerfas PM, et al. ATP7A gene addition to the choroid plexus results in long-term rescue of the lethal copper transport defect in a Menkes disease mouse model. Mol Ther 2011; 19: 2114-2123.
19. Kalinin S, Polak PE, Lin SX, et al. The noradrenaline precursor L-DOPS reduces pathology in a mouse model of Alzheimer's disease. Neurobiol Aging 2012; 33: 1651-1663.
20. Donsante A, Johnson P, Jansen LA, Kaler SG,. Somatic mosaicism in Menkes disease suggests choroid plexus-mediated copper transport to the developing brain. Am J Med Genet A 2010; 152A: 2529-2534.
21. Haddad MR, Macri C, Holmes CS, et al. In utero copper treatment for Menkes disease associated with a severe ATP7A mutation. Mol Genet Metab 2012; 107: 222-228.
22. Lamensdorf I, Eisenhofer G, Harvey-White J, et al. 3,4-Dihydroxyphenyl- acetaldehyde potentiates the toxic effects of metabolic stress in PC12 cells. Brain Res 2000; 868: 191-201.
23. Lamensdorf I, Eisenhofer G, Harvey-White J, et al. Metabolic stress in PC12 cells induces the formation of the endogenous dopaminergic neurotoxin, 3,4-dihydroxyphenyl-acetaldehyde. J Neurosci Res 2000; 60: 552-558.
24. Marchitti SA, Deitrich RA, Vasiliou V,. Neurotoxicity and metabolism of the catechol-amine-derived 3,4-dihydroxyphenylacetaldehyde and 3,4-dihydroxyphenyl-glycolaldehyde: the role of aldehyde dehydrogenase. Pharmacol Rev 2007; 59: 125-150.
25. Mattammal MB, Haring JH, Chung HD, et al. An endogenous dopaminergic neurotoxin: implication for Parkinson's disease. Neurodegeneration 1995; 4: 271-281.
26. Holmes C, Whittaker N, Heredia-Moya J, Goldstein DS,. Contamination of the norepinephrine prodrug L-DOPS by dihydroxyphenylacetaldehyde. Clin Chem 2010; 56: 832-838.
27. Burke WJ, Chung HD, Li SW,. Quantitation of 3,4- dihydroxyphenylacetaldehyde and 3, 4-dihydroxyphenylglycolaldehyde, the monoamine oxidase metabolites of dopamine and noradrenaline, in human tissues by microcolumn high-performance liquid chromatography. Anal Biochem 1999; 273: 111-116.